Jasper Therapeutics, Inc. announced that the first patient has been dosed in a Phase 1 trial evaluating briquilimab as second-line therapy in subjects with lower-risk myelodysplastic syndrome. The open-label, single-arm Phase 1 trial will evaluate the safety and tolerability of briquilimab as a second-line therapy in subjects with LR-MDS. The trial will employ a 3+3 dose escalation design to identify the maximum tolerated dose or optimal biologic dose and recommended Phase 2 dose of briquilimab monotherapy as a chronic therapeutic for LR-MDS patients with documented cytopenia such as red blood cell transfusion dependence, thrombocytopenia or neutropenia.

The trial will be conducted at Moffitt Cancer Center in Tampa, FL, and is expected to enroll up to 30 patients that will receive briquilimab every 56 days for 4 consecutive cycles.